8-67506804-G-C
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2
The NM_020361.5(CPA6):āc.619C>Gā(p.Gln207Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00198 in 1,611,506 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_020361.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CPA6 | NM_020361.5 | c.619C>G | p.Gln207Glu | missense_variant | Exon 6 of 11 | ENST00000297770.10 | NP_065094.3 | |
CPA6 | XM_017013646.2 | c.175C>G | p.Gln59Glu | missense_variant | Exon 6 of 11 | XP_016869135.1 | ||
CPA6 | XM_017013647.2 | c.619C>G | p.Gln207Glu | missense_variant | Exon 6 of 7 | XP_016869136.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00122 AC: 186AN: 152174Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00146 AC: 366AN: 251082Hom.: 0 AF XY: 0.00153 AC XY: 207AN XY: 135684
GnomAD4 exome AF: 0.00206 AC: 3001AN: 1459214Hom.: 4 Cov.: 29 AF XY: 0.00202 AC XY: 1466AN XY: 726034
GnomAD4 genome AF: 0.00122 AC: 186AN: 152292Hom.: 0 Cov.: 32 AF XY: 0.00106 AC XY: 79AN XY: 74468
ClinVar
Submissions by phenotype
Familial temporal lobe epilepsy 5 Pathogenic:1Uncertain:2
- -
This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. -
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -
not provided Uncertain:3
- -
- -
Reported in cis with G267R in an individual with early onset epileptic encephalopathy, inherited from the individual's mother who was reported to have unexplained epilepsy but not epileptic encephalopathy (Allen et al., 2016) Reported in an individual with temporal lobe epilepsy who was also heterozygous for the G267R variant, but familial segregation information was not included (Sapio et al., 2012) In silico analysis supports that this missense variant has a deleterious effect on protein structure/function This variant is associated with the following publications: (PMID: 32581362, 29358611, 23105115, 26648591) -
not specified Uncertain:1Benign:1
- -
Variant summary: CPA6 c.619C>G (p.Gln207Glu) results in a conservative amino acid change located in the Peptidase M14, carboxypeptidase A domain (IPR000834) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.002 in 1611506 control chromosomes in the gnomAD database, including 4 homozygotes, suggesting the variant could be benign. c.619C>G has been reported in the literature in individuals of heterozygous or unspecified genotype affected with neurodevelopmental disorders including focal or progressive myoclonic epilepsy, early onset epileptic encephalopathy, intellectual disability, cerebral palsy, or other unspecified neurodevelopmental disorder all without evidence of causality, often found in cis or unknown phase with c.799G>A, p.G267R (e.g. Sapio_2012, Muona_2014, Allen_2015, Moortgat_2018, vanEyk_2021, Sanchis-Juan_2023, Coppola_2023). These reports do not provide unequivocal conclusions about association of the variant with CPA6-Related Disorders. At least one publication reports experimental evidence evaluating an impact on protein function showing severely reduced CPA6 activity and protein expression in vitro (e.g. Sapio_2012). The following publications have been ascertained in the context of this evaluation (PMID: 26648591, 38088023, 29180823, 25401298, 37541188, 23105115, 34531397). ClinVar contains an entry for this variant (Variation ID: 393467). Based on the evidence outlined above, the variant was classified as VUS-possibly benign. -
Febrile seizures, familial, 11 Benign:2
- -
- -
Self-limited epilepsy with centrotemporal spikes Pathogenic:1
CAADphred>15 -
Confusion;C0030252:Palpitations;C0036572:Seizure;C0156404:Irregular menstruation;C0751495:Focal-onset seizure;C4020949:Abnormal emotional state;C5399973:Periventricular heterotopia Pathogenic:1
- -
Global developmental delay Uncertain:1
- -
Familial temporal lobe epilepsy 5;C3280734:Febrile seizures, familial, 11 Uncertain:1
The inherited missense variant c.619C>G (p.Gln207Glu) in the CPA6 gene has been reported in the literature in individuals affected with epilepsy [PMIDs: 21922598, 23105115, 26648591]. The variant has 0.001222 allele frequency in the gnomAD(v3) database (186 out of 152174 heterozygous alleles, no homozygotes). It affects evolutionarily conserved residues and is predicted deleterious by multiple in silico prediction tools. In vitro functional expression studies in cellular assays suggest that the variant reduces the CPA6 enzymatic activity compared to wild type protein [PMIDs: 21922598, 23105115]. However, additional studies are needed to determine the clinical significance of this variant. Based on the available evidence, the inherited heterozygous missense variants [c.619C>G(p.Gln207Glu)identified in the CPA6 gene is reported as a variant of uncertain significance. -
Epilepsy Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at